(Diphtheria + pertussis (acellular) + tetanus) vaccine is under clinical development by BioNet-Asia and currently in Phase III for Tetanus. According to GlobalData, Phase III drugs for Tetanus have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how (Diphtheria + pertussis (acellular) + tetanus) vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Diphtheria + pertussis (acellular) + tetanus) vaccine overview
TdaP vaccine is under development for the prevention of pertusis, tetanus and diphtheria. The vaccine candidate is administered intramuscularly. It constitutes of recombinant acellular pertussis vaccine containing recombinant genetically detoxified pertussis toxin (PTgen), filamentous hemagglutinin (FHA) and pertactin (PRN) in combination with tetanus and diphtheria toxoids.
BioNet-Asia overview
BioNet-Asia (BioNet) is a unique vaccine expertise offering through its networks access to technology, products and markets. BioNet is headquartered in Bangkok, Thailand.
For a complete picture of (Diphtheria + pertussis (acellular) + tetanus) vaccine’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
